课题基金 / 基金详情

CARDIAC FUNCTION AND PROTECTION IN CARDIOGENIC SHOCK

CARDIAC FUNCTION AND PROTECTION IN CARDIOGENIC SHOCK
心源性休克中的心脏功能和保护
批准号:
2224777
负责人:
CARL S APSTEIN
金额:
$33.6万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-12-01 至 1996-11-30

项目摘要

项目成果

CARL S APSTEIN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The overall goal is to develop pharmacologic and metabolic strategies to improve cardiac function during acute ischemic failure (cariogenic shock), without increasing ischemic injury, to maintain function until revascularization can be done. The left ventricle in cariogenic shock is composed of a large region (40%) which is severely ischemic, infarcting, and non-contractile, and a non-occluded region which is acutely overloaded and undergoes progressive contractile failure leading to systemic hypotension. With hypotension coronary perfusion pressure decreases and this non-occluded region becomes moderately ischemic. The ischemia accelerates the failure creating a "vicious cycle," and a mortality rate 90%. The proposed research will develop strategies to maintain contractile function of over-loaded moderately ischemic myocardium which will serve as a model of the non-occluded region of the cariogenic shock ventricle after it has developed acute overload, progressive ischemia and failure. The isolated isovolumic (balloon in LV) blood perfused rabbit heart preparation will be used to model the myocardial perfusion and loading conditions in cariogenic shock. Isolated hearts will be subjected to either a ligation of the left main coronary artery or to global low flow ischemia (50% decrease in global coronary flow). Cardiac function and injury will be assessed by measures of systolic and diastolic function, coronary vasomotion, magnetization transfer, ATP, creatine phosphate and glycogen contents and loss of myocardial creatine kinase activity. Studies will be done in non- hypertrophied hearts and in hearts with hypertrophy secondary to chronic myocardial infarction since cariogenic shock often occurs in patients with a previous infarct and secondary hypertrophy. Interventions will be assessed for their efficacy in reversing or inhibiting the following components of ischemic pathophysiology: decreased contractile (systolic) function, increased diastolic dysfunction, high energy phosphate supple/demand mismatch, and inadequate coronary vasodilation. The goal will be to maximize active systolic tension generation while minimizing any increase myofilament sensitivity to calcium, and which block inorganic phosphate's effect to decrease active tension during ischemia. Inhibition of cardiac angiotensin converting enzyme and the protein kinase C system will be studied as interventions to reduce ischemic diastolic dysfunction. Increased levels of selected substrates will be provided to test the hypothesis that overloaded myocardium may become substrate limited during sustained low-flow ischemia and to attempt to improve the high energy phosphate supply/demand mismatch; their efficacy will be measured by 31-P NMR magnetization transfer to measure ATP turnover. The impaired intrinsic coronary vasodilator response to low- flow ischemia will be reversed with coronary vasodilator. The overall hypothesis is that the separate components of myocardial ischemic depression of function and injury need to be corrected in combination. Improved function of ischemic myocardium should reduce the high mortality rate of cariogenic shock.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ISCHEMIA REPERFUSION & OXIDANT STRESS IN G6PD DEFICIENCY
  • 批准号:
    6661510
  • 项目类别:
  • 资助金额:
    $22.0万
  • 财政年份:
    2002
  • 负责人:
    CARL S APSTEIN
  • 依托单位:
ISCHEMIA REPERFUSION & OXIDANT STRESS IN G6PD DEFICIENCY
  • 批准号:
    6500787
  • 项目类别:
  • 资助金额:
    $22.0万
  • 财政年份:
    2001
  • 负责人:
    CARL S APSTEIN
  • 依托单位:
ISCHEMIA REPERFUSION & OXIDANT STRESS IN G6PD DEFICIENCY
  • 批准号:
    6356563
  • 项目类别:
  • 资助金额:
    $22.0万
  • 财政年份:
    2000
  • 负责人:
    CARL S APSTEIN
  • 依托单位:
ISCHEMIC REPERFUSION INJURY IN HYPERTENSIVE AND HYPERTROPHIED HEARTS
  • 批准号:
    6202466
  • 项目类别:
  • 资助金额:
    $27.77万
  • 财政年份:
    1999
  • 负责人:
    CARL S APSTEIN
  • 依托单位:
国内基金
海外基金
靶向HIF-1α调控IFN-γ-STAT1/HIF1α-glycolysis信号轴抑制重症H1N1感染诱导的急性肺脏和胸腺免疫病理损伤
  • 批准号:
    82370017
  • 项目类别:
    面上项目
  • 资助金额:
    49万元
  • 批准年份:
    2023
  • 负责人:
    刘波
  • 依托单位: